Abstract
Various pharmacological agents designed to modulate plasma membrane ion channels seem to significantly affect intracellular Ca2+ signaling when acting on their target receptor. Some agents could also cross-react (modulate channels or receptors beyond their putative target) with intracellular Ca2+ transporters. This study investigated the potential of thirty putative modulators of either plasma membrane K+, Na+, or transient receptor potential (TRP) channels to cross-react with intracellular Ca2+ release channels [i.e., ryanodine receptors (RyRs)] from skeletal muscle sarcoplasmic reticulum (SR). Screening for cross-reactivity of these various agents was performed by measuring the rate of spontaneous Ca2+ leak or caffeine-induced Ca2+ release from SR microsomes. Four of the agents displayed a strong cross-reactivity and were further evaluated with skeletal RyR (RyR1) reconstituted into planar bilayers. 6,12,19,20,25,26-Hexahydro-5,27:13,18:21,24-trietheno-11,7-metheno-7H-dibenzo [b,n][1,5,12,16]tetraazacyclotricosine-5, 13-diium dibromide (UCL 1684; K+ channel antagonist) and lamotrigine (Na+ channel antagonist) were found to significantly inhibit the RyR1-mediated caffeine-induced Ca2+ release. TRP channel agonists anandamide and (−)menthol were found to inhibit and activate RyR1, respectively. High concentrations of nine other agents produced partial inhibition of RyR1-mediated Ca2+ release from SR microsomes. Various pharmacological agents, especially TRP modulators, also inhibited a minor RyR1-independent component of the SR Ca2+ leak. Overall, ∼43% of the agents selected cross-reacted with RyR1-mediated and/or RyR1-independent Ca2+ leak from intracellular stores. Thus, cross-reactivity should be considered when using these classes of pharmacological agents to determine the role of plasmalemmal channels in Ca2+ homeostasis.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Institutes of Health [Grant R01 GM078665].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.071167.
-
ABBREVIATIONS:
- RyR
- ryanodine receptor
- RyR1
- skeletal RyR
- SR
- sarcoplasmic reticulum
- SERCA
- sarco(endo)plasmic reticulum Ca2+ ATPase
- CGP-37157
- 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one
- TRP
- transient receptor potential
- APIII
- antipyrylazo III
- CPZ
- cyclopiazonic acid
- BAPTA
- 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
- Po
- open probability
- RTX
- resiniferatoxin
- RR
- ruthenium red
- UCL 1684
- 6,12,19,20,25,26-hexahydro-5,27:13,18:21,24-trietheno-11,7-metheno-7H-dibenzo [b,n][1,5,12,16]tetraazacyclotricosine-5,13-diium dibromide
- (−)menthol
- (1R,2S,5R)-2-isopropyl-5-methylcyclohexanol.
- Received January 12, 2011.
- Accepted June 10, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|